Takeda Pharmaceutical Co Adr (TAK)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Takeda Pharmaceutical Co Adr

Healthcare (1124)

@takedapharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

TAK's Discussions on Twitter

Vergleichen Sie TAK mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TAK Takeda Pharmaceutical Co Adr	14.37	45.05B	29.63B	260.53M	5.51B	0.0788
ZTS Zoetis Inc	118.07	51.01B	9.40B	2.65B	2.24B	5.935
HLN Haleon Plc Adr	9.46	41.46B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	29.80	32.77B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	484.86	20.51B	3.08B	1.24B	1.07B	25.61

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-02	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-03-16	Hochstufung	BofA Securities	Neutral → Buy
2022-07-19	Hochstufung	Cowen	Market Perform → Outperform
2021-10-07	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-04-19	Herabstufung	JP Morgan	Overweight → Neutral
2019-11-01	Eingeleitet	Cowen	Market Perform
2019-08-15	Herabstufung	Daiwa Securities	Outperform → Neutral

Alle ansehen

Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten

Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)

Takeda Pharmaceutical Co Adr (TAK)

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Vergleichen Sie TAK mit anderen Aktien

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten

Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.

Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz

INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com

Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛

Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria

CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com

BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com

CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se

INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com

INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com

Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN

Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo

Pharma stocks in Asia fall as Trump announces 100% tariffs - Investing.com

5 Best High-Yield Dividend Stocks to Buy Now - The Motley Fool

Takeda’s narcolepsy drug shows positive results in phase 3 trials - Investing.com

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se

Japan's Takeda weighs India for global trials to speed up drug launches - MSN

Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN

IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl

IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN

IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - inkl

Waltham biotech’s latest pharma deal valued at $2B - The Business Journals

TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com

Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World

Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie TAK